GoPro Inc. said it may not be able to operate for another year, triggering a sharp decline in its share price on Monday [1], [2].
The warning signals a critical liquidity crisis for the company, suggesting that the pioneer of action cameras is struggling to maintain basic operational viability. If the firm cannot secure additional financing, it faces the possibility of insolvency.
In updated financial statements filed with the SEC, GoPro said there is "substantial doubt" [4] regarding its ability to continue as a going concern for the next 12 months [3]. The company identified rising memory-chip costs and pressure to meet debt covenants as primary factors straining its liquidity [5].
Market reaction was immediate. Shares of the company, traded on the NASDAQ, dropped eight percent during premarket trading [1]. As the trading day progressed and the severity of the warning became clearer, the stock declined by 14% [2].
These financial headwinds follow a period of instability regarding the company's debt obligations. GoPro entered into a covenant-compliance arrangement in February 2026 [6] to manage its existing financial commitments. However, the latest filing indicates that those measures may be insufficient to ensure long-term survival.
The company has not specified the exact amount of additional financing required to stabilize its balance sheet. The current situation reflects a broader struggle to manage hardware production costs while navigating strict lending requirements.
“GoPro said there is "substantial doubt" regarding its ability to continue as a going concern.”
A going-concern warning is a formal accounting disclosure that indicates a company is at high risk of bankruptcy. For GoPro, the combination of rising component costs—specifically memory chips—and the inability to easily satisfy debt covenants suggests a narrowing window to restructure its finances. The sharp stock decline reflects investor concern that the company's current cash flow is insufficient to sustain operations without a significant capital injection or a drastic change in its cost structure.
